Skip to main content
EasyJIA score - a tool developed to refer juvenile pts w/ MSK sxs for rheum referral. 342 pts, (18%) Dx w/ JIA. 8 variab

Dr. John Cush RheumNow

8 months 2 weeks ago
EasyJIA score - a tool developed to refer juvenile pts w/ MSK sxs for rheum referral. 342 pts, (18%) Dx w/ JIA. 8 variables (10 total points) includes large Jts, daily Sxs, JT swelling, activity precipitating, +squeeze test, bending IP Jts, limping/stiffness, SI Pain. You need 3 https://t.co/zcCRUkuqh8
ADJUST trial (248 JIA pts w/ Uveitis & inactive >6mos, either continued or weaned off adalimumab. ADA weaning res

Dr. John Cush RheumNow

8 months 2 weeks ago
ADJUST trial (248 JIA pts w/ Uveitis & inactive >6mos, either continued or weaned off adalimumab. ADA weaning resulted in more flares (68% vs 14%, mostly uveitis) w/ no protection from background DMARD Rx. Restarting ADA was mostly effective. https://t.co/ZWHfPl2UNl https://t.co/xodyrbaQOj
2025 Lancet review https://t.co/Qbwup6QxZK of Osteoarthritis did not mention/endorse Rx w/ platelet rich plasma (PRP) p

Dr. John Cush RheumNow

8 months 2 weeks ago
2025 Lancet review https://t.co/Qbwup6QxZK of Osteoarthritis did not mention/endorse Rx w/ platelet rich plasma (PRP) prompting several letters of protest. Read the authors response: Despite the popularity of PRP, there are few PBO controlled high quality studies to prove its https://t.co/7pCZV9CHfJ
NJ Senate (Senate Bill No. 3560) has voted to permite Physician Assistans to enter the Interstate Physician Assistant Li

Dr. John Cush RheumNow

8 months 2 weeks ago

NJ Senate (Senate Bill No. 3560) has voted to permite Physician Assistans to enter the Interstate Physician Assistant Licensure Compact, designed to streamline PA licensing to work in multiple states https://t.co/VE1DdWuFwM https://t.co/szJzShVAaz

Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. 
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 &

Dr. John Cush RheumNow

8 months 2 weeks ago
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/OOctcfI1sT
Systematic review of Apremilast in soriasis and Psoriatic Arthritis: 28 RCTs involving 6825 patients. Efficacy ( PASI 7

Dr. John Cush RheumNow

8 months 2 weeks ago
Systematic review of Apremilast in soriasis and Psoriatic Arthritis: 28 RCTs involving 6825 patients. Efficacy ( PASI 75 and ACR 20) observed at APR 30 mg or 20 mg bid (RR > 2) & both doses did not affect CRP levels. GI side effx most common (see figure) https://t.co/YqfaWPvmTm https://t.co/z8PfJqp0CJ
DANFLU-2 RCT of 332 438 elderly (43 881 w/ diabetes) tested high (HD-IIV) vs standard dose SD-IIV) flu vaccine. HD-I

Dr. John Cush RheumNow

8 months 2 weeks ago
DANFLU-2 RCT of 332 438 elderly (43 881 w/ diabetes) tested high (HD-IIV) vs standard dose SD-IIV) flu vaccine. HD-IIV signif. reduced cardioresp., CV, CHF, influenza, hospitalizations vs SD-IIV, irrespective of DM status. Similar results previously seen in a Canadian RA pop. https://t.co/GGZPThoHrs
QD Clinic: Tophi Tales: Management of Uncontrolled Gout Daric Mueller, PA-C and Andrew Sulich, MD, St. Clair Shores, M

Dr. John Cush RheumNow

8 months 2 weeks ago

QD Clinic: Tophi Tales: Management of Uncontrolled Gout Daric Mueller, PA-C and Andrew Sulich, MD, St. Clair Shores, MI, present this QD Clinic: Tophi Tales: Management of Uncontrolled Gout. This QD Clinic is presented as part of RheumNow's "Mission: APP Partners in Care" https://t.co/7JTbC0223I

GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis

Lilly announced the topline results from its phase 3b

Dr. John Cush RheumNow

8 months 2 weeks ago
GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w
2025 Rheumatologists, In Memorium

In 2025, rheumatology lost many of its most influential clinicians, mentors, and coll

Dr. John Cush RheumNow

8 months 2 weeks ago
2025 Rheumatologists, In Memorium In 2025, rheumatology lost many of its most influential clinicians, mentors, and colleagues. This honor roll recognizes those who cared for countless patients, shaped generations of rheumatologists, and left a lasting legacy in our field. As Dr. https://t.co/MMa670vsoH
J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn bl

Dr. John Cush RheumNow

8 months 3 weeks ago
J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn blocker that reduces AutoAbs & B cell activity. Study met its 24 wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://t.co/KMseKyGirt
Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, an

Dr. John Cush RheumNow

8 months 3 weeks ago
Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty. Register: https://t.co/MVgXnacU5q https://t.co/7ajH7Ry0Uj
“The practice of medicine is an art, not a trade; a calling, not a business; a calling in which your heart will be exe

Dr. John Cush RheumNow

8 months 3 weeks ago
“The practice of medicine is an art, not a trade; a calling, not a business; a calling in which your heart will be exercised equally with your head. – Sir William Osler
Anti-mitochondrial M2 Ab (AMA-M2) in 987 IIM pts-- 55 (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of pol

Dr. John Cush RheumNow

8 months 3 weeks ago
Anti-mitochondrial M2 Ab (AMA-M2) in 987 IIM pts-- 55 (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of polymyositis (56% vs 23.5%), GGT, alk phos levels, & 3 fold more cardiac involvement (60 vs 13%) (arrhythmias, CHF, pulm HTN (31-56%), but no effect on survival https://t.co/8fQzgRfHr4
×